Mark Goldsmith has filed 58 Form 4 transactions, all in a single company, Revolution Medicines (RVMD). The pattern is one-sided: zero open-market purchases and $57.3 million in total sales. The recent activity, spanning March through September 2026, shows 22 sales and no buys. The largest single transaction was an $18.0 million sale on April 15, 2026, followed by a $7.5 million sale on August 21, 2026, and a $5.2 million sale the same day. Smaller sales on August 21 ranged from roughly $26,000 to $1.4 million, indicating a systematic liquidation of holdings across multiple lots.
The transaction codes clarify the mechanics. Two option exercises appear in the data: $378,400 on August 21 and a combined $552,724 on April 15. These are marked as code M, which is a mechanical exercise, not a discretionary purchase. The sales themselves are all code S, open-market sales. There are no code P purchases, no gifts, and no conversions. The dollar values of the sales far exceed the exercise values, meaning Goldsmith sold more shares than he acquired through options during this window.
The concentration in RVMD is total. Every trade in the recent list references the same ticker, and the dates cluster around quarterly intervals: March 17, April 15, June 16, August 21, and September 16. The August 21 cluster contains 17 separate transactions, the heaviest single-day activity. The cumulative effect is a steady reduction of RVMD exposure, with no corresponding accumulation. The data shows a clear selling bias over the six-month period, with the largest disposals occurring in April and August.
AI-assisted summary